Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Renal Cell 52Kidney Neoplasms 43Melanoma 23Neoplasm Metastasis 14Uterine Cervical Neoplasms 8Breast Neoplasms 5Vaginal Neoplasms 4Penile Neoplasms 4Pancreatic Neoplasms 4Oropharyngeal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Anus Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Wilms Tumor 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 82Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25enfortumab vedotin 24Cystoscopy 24Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × aldesleukin × Genitourinary × Clear all
NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡